| Theme | Cytomegalovirus enterocolitis and Clostridium difficile infection | |
|---|---|---|
| Title | Treatment and outcome of cytomegalovirus enteritis | |
| Publish Date | 2015/11 | |
| Author | Nobuaki Kuno | Division of Gastroenterology, Matsuyama Red Cross Hospital |
| Author | Koichi Kurahara | Division of Gastroenterology, Matsuyama Red Cross Hospital |
| Author | Hiroki Yaita | Division of Gastroenterology, Matsuyama Red Cross Hospital |
| Author | Yumi Oshiro | Department of Pathology, Matsuyama Red Cross Hospital |
| Author | Tomohiro Nagasue | Division of Gastroenterology, Matsuyama Red Cross Hospital |
| Author | Akira Harada | Division of Gastroenterology, Matsuyama Red Cross Hospital |
| Author | Masashi Kameda | Division of Gastroenterology, Matsuyama Red Cross Hospital |
| Author | Takahide Tanaka | Division of Gastroenterology, Matsuyama Red Cross Hospital |
| Author | Tadahiko Fuchigami | Division of Gastroenterology, Matsuyama Red Cross Hospital |
| [ Summary ] | Cytomegalovirus (CMV) enteritis (or colitis) is generally diagnosed in immunocompromised patients in association with human immunodeficiency virus infection and in recipients of solid organ or hematopoietic stem cell transplant. Recently, CMV enteritis was also reported in immunocompetent patients. Antiviral therapy is beneficial in immunocompetent patients with CMV enteritis. For otherwise immunocompetent patients, CMV enteritis usually does not require treatment. In elderly individuals, even those who are immunocompetent, CMV enteritis may result in major complications such as bowel perforation and should be included in the differential diagnosis of abdominal symptoms if it is resistant to conventional treatment. | |